Pioglitazone indications
You don't need to be Editor-In-Chief to add or edit content to WikiDoc. You can begin to add to or edit text on this WikiDoc page by clicking on the edit button at the top of this page. Next enter or edit the information that you would like to appear here. Once you are done editing, scroll down and click the Save page button at the bottom of the page.
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Phone:617-632-7753
List of indications
Glycemic control
Management of type 2 diabetes
Glycemic control
Pioglitazone is indicated as an adjunct to diet and exercise to improve glycemic control in
patients with type 2 diabetes (non-insulin-dependent diabetes mellitus, NIDDM). Pioglitazone
is indicated for monotherapy. Pioglitazone is also indicated for use in combination with a
sulfonylurea, metformin, or insulin when diet and exercise plus the single agent does
not result in adequate glycemic control. Return to top
Management of type 2 diabetes
Management of type 2 diabetes should also include nutritional counseling, weight reduction
as needed, and exercise. These efforts are important not only in the primary
treatment of type 2 diabetes, but also to maintain the efficacy of drug therapy. Return to top
The content of this page is taken from the FDA package insert for this drug and should not be edited.
Acknowledgement and Attribution Regarding Sources of Content
Some of the initial content on this page may be incorporated in part from copyleft sources in the public domain including wikis such as Wikipedia and AskDrWiki. Drug information for patients came from the The National Library of Medicine. Infectious disease information may have come from the Centers for Disease Control (CDC). Differential Diagnoses are drawn from clinicians as well as an amalgamation of 3 sources: 1.The Disease Database; 2. Kahan, Scott, Smith, Ellen G. In A Page: Signs and Symptoms. Malden, Massachusetts: Blackwell Publishing, 2004:3; 3. Sailer, Christian, Wasner, Susanne. Differential Diagnosis Pocket. Hermosa Beach, CA: Borm Bruckmeir Publishing LLC, 2002:7 .
